Coronavirus disease 2019 in immunocompromised patients: a comprehensive review of coronavirus disease 2019 in hematopoietic stem cell recipients
| Autor: | Swann Bredin, Asma Mabrouki, Raphaël Clere-Jehl, Elise Yvin, Elie Azoulay, Yannick Binois, Antoine Lafarge |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Coronavirus disease 2019 (COVID-19) medicine.medical_treatment Population Hematopoietic stem cell transplantation Critical Care and Intensive Care Medicine coronavirus disease 2019 Immunocompromised Host Immune system Internal medicine medicine Humans education education.field_of_study SARS-CoV-2 business.industry RESPIRATORY SYSTEM: Edited by Giacomo Grasselli COVID-19 Hematopoietic stem cell Immunosuppression Hematopoietic Stem Cells Vaccination Transplantation immunocompromised surgical procedures operative medicine.anatomical_structure hematopoietic stem cell transplantation business |
| Zdroj: | Current Opinion in Critical Care |
| ISSN: | 1531-7072 1070-5295 |
| DOI: | 10.1097/mcc.0000000000000907 |
| Popis: | Purpose of review Immunocompromised patients are notably vulnerable to severe coronavirus disease 2019. This review summarizes COVID-19 features and outcomes in autologous and allogeneic hematopoietic stem cell transplantation (HSCT) recipients. Recent findings Recent findings suggest that HSCT recipients exhibit a high burden of comorbidities and COVID-19 clinical features almost similar to the general COVID population. Furthermore, HSCT recipients exhibit a protracted SARS-CoV-2 shedding, prolonging duration of symptoms and promoting the generation of highly mutated viruses. Last, most of studies report a higher COVID-19 mortality in HSCT recipients, mainly driven by age, comorbidities, time from transplantation, and immunosuppression because of both treatments and underlying hematological malignancy. Summary Further studies are warranted to determine the proper impact of HSCT-related immune disorders on COVID-19 outcomes, and to evaluate specific treatments and vaccination strategy in this high-risk population. Taken together, those findings emphasize the need for more rigorous surveillance and preemptive measures for all HSCT recipients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|